Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
ACS Infect Dis ; 10(3): 917-927, 2024 03 08.
Article de Anglais | MEDLINE | ID: mdl-38346249

RÉSUMÉ

HIV-1 integrase (IN) is an important molecular target for the development of anti-AIDS drugs. A recently FDA-approved second-generation integrase strand transfer inhibitor (INSTI) cabotegravir (CAB, 2021) is being marketed for use in long-duration antiviral formulations. However, missed doses during extended therapy can potentially result in persistent low levels of CAB that could select for resistant mutant forms of IN, leading to virological failure. We report a series of N-substituted bicyclic carbamoyl pyridones (BiCAPs) that are simplified analogs of CAB. Several of these potently inhibit wild-type HIV-1 in single-round infection assays in cultured cells and retain high inhibitory potencies against a panel of viral constructs carrying resistant mutant forms of IN. Our lead compound, 7c, proved to be more potent than CAB against the therapeutically important resistant double mutants E138K/Q148K (>12-fold relative to CAB) and G140S/Q148R (>36-fold relative to CAB). A significant number of the BiCAPs also potently inhibit the drug-resistant IN mutant R263K, which has proven to be problematic for the FDA-approved second-generation INSTIs.


Sujet(s)
Inhibiteurs de l'intégrase du VIH , Intégrase du VIH , Raltégravir de potassium/pharmacologie , Inhibiteurs de l'intégrase du VIH/pharmacologie , Pyridones/pharmacologie , Intégrase du VIH/génétique
2.
Org Process Res Dev ; 27(5): 847-853, 2023 May 19.
Article de Anglais | MEDLINE | ID: mdl-37229216

RÉSUMÉ

Dolutegravir (DTG), Bictegravir (BIC), and Cabotegravir (CAB) are the second-generation integrase strand transfer inhibitors (INSTIs) that have been FDA-approved for the treatment of HIV-1 infection. Preparation of these INSTIs utilizes the common intermediate 1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (6). Presented herein is a literature and patent review of synthetic routes used to access the pharmaceutically important intermediate 6. The review highlights the ways in which small fine-tuned synthetic modifications have been used to achieve good yields and regioselectivity of ester hydrolysis.

3.
Molecules ; 28(3)2023 Feb 02.
Article de Anglais | MEDLINE | ID: mdl-36771093

RÉSUMÉ

An efficient one-pot synthetic method has been developed for the preparation of bicyclic carbamoyl pyridones from the known common intermediate methyl 5-((2,4-difluorobenzyl)carbamoyl)-1-(2,2-dimethoxyethyl)-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate (8). The scalable protocol is facile and employs readily available reagents, needing only a single purification as the final step. The utility of the approach was demonstrated by preparing a library of HIV-1 integrase strand transfer inhibitors (INSTIs) that differ by the presence or absence of a double bond in the B-ring of the bicyclic carbamoyl pyridines 6 and 7. Several of the analogs show good antiviral potencies in single-round HIV-1 replication antiviral assays and show no cytotoxicity in cell culture assays. In general, the compounds with a B-ring double bond have higher antiviral potencies than their saturated congeners. Our methodology should be applicable to the synthesis of a range of new metal-chelating analogs.


Sujet(s)
Infections à VIH , Inhibiteurs de l'intégrase du VIH , Intégrase du VIH , Humains , Pyridones/composition chimique , Raltégravir de potassium/pharmacologie , Inhibiteurs de l'intégrase du VIH/composition chimique , Résistance virale aux médicaments , Intégrase du VIH/composition chimique , Antiviraux/pharmacologie , Antiviraux/usage thérapeutique , Composés hétérocycliques 3 noyaux/pharmacologie , Infections à VIH/traitement médicamenteux
4.
Org Lett ; 20(7): 2092-2095, 2018 04 06.
Article de Anglais | MEDLINE | ID: mdl-29578718

RÉSUMÉ

A novel silver-mediated oxidative decarboxylative intramolecular asymmetric radical cyclization has been developed to form a Csp3-Csp2 bond via memory of chirality. The application of the process has been demonstrated for the synthesis of the circumdatin class of alkaloids in high enantiopurity with retention of the configuration. The developed protocol is mild and works with an inexpensive silver catalyst in the absence of ligand, base, or additives. The involvement of a monoradical in the reaction has been established by trapping the radical intermediate.

5.
Inorg Chem ; 55(22): 12052-12060, 2016 Nov 21.
Article de Anglais | MEDLINE | ID: mdl-27934311

RÉSUMÉ

A new 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-based probe molecule (L) is synthesized for specific binding to Hg2+ ion in physiological condition with an associated luminescence ON response in the near-IR region of the spectrum. Appropriate functionalization in the 5-position of each of two pyrrole moieties with styryl functionality in a BODIPY core helped us in achieving the extended conjugation and a facile intramolecular charge transfer transition with a narrow energy gap for frontier orbitals. This accounted for a poor emission quantum yield for the probe molecule L. Binding to Hg2+ helped in interrupting the facile intramolecular charge transfer (ICT) process that was initially operational for L. This resulted in a hypsochromic shift of absorption band and a turn-on luminescence response with λMaxEms of 650 nm on specific binding to Hg2+. Observed spectral changes are rationalized based on quantum chemical calculations. Interestingly, this reagent is found to be localized preferentially in the mitochondria of the live human colon cancer (Hct116) cells. Mitochondria is one of the major targets for localization of Hg2+, which actually decreases the mitochondrial membrane potential and modifies various proteins having sulfudryl functionality(ies) to cause cell apoptosis. Considering these, ability of the present reagent to specifically recognize Hg2+ in the mitochondrial region of the live Hct116 cells has significance.


Sujet(s)
Mercure/métabolisme , Mitochondries/métabolisme , Sondes moléculaires , Spectroscopie proche infrarouge/méthodes , Eau/composition chimique , Cellules HCT116 , Humains
6.
Org Lett ; 18(14): 3450-3, 2016 07 15.
Article de Anglais | MEDLINE | ID: mdl-27377995

RÉSUMÉ

The Beckmann rearrangement of ketoximes, mediated by ammonium persulfate-dimethyl sulfoxide as a reagent, has been achieved under neutral conditions. Based on the radical trapping and (18)O-labeling experiments, the transformation follows a mechanism involving a radical pathway. The scope and generality of the developed protocol has been demonstrated by 19 examples. The developed protocol and Pd-catalyzed intramolecular double C-H activation were used as key steps in the formal total synthesis of antimalarial natural product isocryptolepine.


Sujet(s)
Antipaludiques/synthèse chimique , Alcaloïdes indoliques/synthèse chimique , Quinoléines/synthèse chimique , Sulfate d'ammonium/composition chimique , Catalyse , Diméthylsulfoxyde/composition chimique , Piégeurs de radicaux libres/composition chimique , Radicaux libres/composition chimique , Stéréoisomérie
7.
Bioorg Med Chem Lett ; 21(16): 4873-8, 2011 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-21757344

RÉSUMÉ

During our efforts to develop new antifungal agents, a number of hybrid molecules containing furanones and fluconazole pharmacophores were designed and synthesized. The new chemical entities thus synthesized were tested for their potential as antifungal agents against various fungal strains and it was observed that the compounds with general structure 7 were potent inhibitors of Candida albicans ATCC 24433, Candida glabrata ATCC 90030, Candida tropicalis ATCC 750 and Candida neoformans ATCC 34664 while the fluconazole analogues 12 exhibited antifungal activity against Candida albicans ATCC 24433 and Candida glabrata ATCC 90030. The structure-activity relationship for these compounds is discussed. The synthetic strategies used in the present work have potential to prepare a large number of compounds for further refinement of structures to obtain molecules suitable for development as antifungal drugs.


Sujet(s)
Antifongiques/pharmacologie , Candida/effets des médicaments et des substances chimiques , Conception de médicament , Fluconazole/pharmacologie , Furanes/pharmacologie , Antifongiques/synthèse chimique , Antifongiques/composition chimique , Relation dose-effet des médicaments , Fluconazole/composition chimique , Furanes/composition chimique , Tests de sensibilité microbienne , Structure moléculaire , Stéréoisomérie , Relation structure-activité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...